

AMENDMENTS TO THE CLAIMS

This listing of claims replaces all prior versions and listings of claims in the application.


Listing of Claims

Claims 1-24 (canceled)

25. (Previously presented) A pharmaceutical composition comprising a vehicle that comprises (a) an amphipathic oil that is water dispersible and ethanol insoluble, (b) microcrystalline wax and (c) a pharmaceutically acceptable non-aqueous carrier; said vehicle having stably dispersed therein an anti-inflammatory agent in an anti-inflammatorily effective amount.
26. (Previously presented) The composition of Claim 25 that is suitable for intramammary infusion to an udder of a milk producing animal for treatment and/or prevention of an inflammatory condition of the udder.
27. (Previously presented) The composition of Claim 26 wherein the inflammatory condition is associated with mastitis.

Claims 28-32 (canceled)

33. (Previously presented) The composition of Claim 25 wherein the anti-inflammatory agent comprises a non-steroidal anti-inflammatory drug.
34. (Previously presented) The composition of Claim 25 wherein the anti-inflammatory agent comprises a selective COX-2 inhibitor.
35. (Previously presented) The composition of Claim 34 wherein the selective COX-2 inhibitor is a compound having the formula



where R^5 is a methyl or amino group, R^6 is hydrogen or a C_{1-4} alkyl or alkoxy group, X' is N or CR^7 where R^7 is hydrogen or halogen, and Y and Z are independently carbon or nitrogen atoms defining adjacent atoms of a five- to six-membered ring that is optionally substituted at one or more positions with oxo, halo, methyl or halomethyl groups.

36. (Previously presented) The composition of Claim 34 wherein the selective COX-2 inhibitor is selected from the group consisting of deracoxib, parecoxib, celecoxib, valdecoxib, rofecoxib, etoricoxib, lumiracoxib, 2-(3,5-difluorophenyl)-3-[4-(methylsulfonyl)phenyl]-2-cyclopenten-1-one, (S)-6,8-dichloro-2-(trifluoromethyl)-2H-1-benzopyran-3-carboxylic acid, 2-(3,4-difluorophenyl)-4-(3-hydroxy-3-methyl-1-butoxy)-5-[4-(methylsulfonyl)phenyl]-3-(2H)-pyridazinone, 4-[5-(4-fluorophenyl)-3-(trifluoromethyl)-1H-pyrazol-1-yl]benzenesulfonamide, 4-[5-(phenyl)-3-(trifluoromethyl)-1H-pyrazol-1-yl]benzenesulfonamide, salts and prodrugs thereof.
37. (Previously presented) The composition of Claim 34 wherein said selective COX-2 inhibitor is present at a concentration of 0.01 to 1000 mg/ml.
38. (Previously presented) The composition of Claim 34 wherein said selective COX-2 inhibitor is present at a concentration of 0.1 to 750 mg/ml.
39. (Previously presented) The composition of Claim 34 wherein said selective COX-2 inhibitor is present at a concentration of 5 to 250 mg/ml.
40. (Previously amended) The composition of Claim 25 wherein the amphipathic oil

is a polyglycolized glyceride prepared by an alcoholysis reaction of natural triglycerides with polyethylene glycols.

41. (Previously presented) The composition of Claim 40 wherein the polyglycolized glyceride comprises a main fatty acid component of oleic acid or linoleic acid.
42. (Previously presented) The composition of Claim 40 wherein the polyglycolized glyceride comprises a main fatty acid component of oleic acid.
43. (Previously presented) The composition of Claim 40 wherein the polyglycolized glyceride is pegicol 5-oleate.
44. (Previously amended) The composition of Claim 25 wherein the amphipathic oil constitutes 0.01% to 99% weight/volume of the composition.
45. (Previously amended) The composition of Claim 25 wherein the amphipathic oil constitutes 1% to 80% weight/volume of the composition.
46. (Previously presented) The composition of Claim 25 wherein the amphipathic oil constitutes 3% to 25% weight/volume of the composition.
47. (Previously presented) The composition of Claim 25 wherein the microcrystalline wax constitutes 0.001% to 50% weight/volume of the composition.
48. (Previously presented) The composition of Claim 25 wherein the microcrystalline wax constitutes 0.1% to 40% weight/volume of the composition.
49. (Previously presented) The composition of Claim 25 wherein the microcrystalline wax constitutes 1% to 15% weight/volume of the composition.
50. (Previously amended) The composition of Claim 25 wherein the non-aqueous carrier is selected from the group consisting of vegetable oils, mineral oils, medium to long chain fatty acids and alkyl esters thereof, propylene glycol diesters of medium to long chain fatty acids, mono-, di-, and triglyceryl esters of fatty acids, polyethylene glycols, and combinations thereof.

51. (Previously presented) The composition of Claim 50 wherein the non-aqueous carrier is a vegetable oil selected from the group consisting of cottonseed oil, corn oil, sesame oil, soybean oil, olive oil, coconut oil, fractionated coconut oils, peanut oil, sunflower oil, safflower oil, almond oil, avocado oil, palm oil, palm kernel oil, babassu oil, beechnut oil, linseed oil, rape oil and combinations thereof.
52. (Previously presented) The composition of Claim 50 wherein the non-aqueous carrier is cottonseed oil.
53. (Previously presented) The composition of Claim 50 wherein the non-aqueous carrier comprises capric acid in an amount of 20% to 45% and caprylic acid in an amount of 45% to 80% by weight of the non-aqueous carrier.
54. (Previously amended) The composition of Claim 25 wherein the non-aqueous carrier constitutes 0.5% to 99% weight/volume of the composition.
55. (Previously amended) The composition of Claim 25 wherein the non-aqueous carrier constitutes 10% to 95% weight/volume of the composition.
56. (Previously amended) The composition of Claim 25 wherein the non-aqueous carrier constitutes 40% to 90% weight/volume of the composition.
57. (Previously amended) The composition of Claim 25 that further comprises at least one excipient selected from the group consisting of antioxidants, preservatives, stabilizers, wetting agents, lubricants, emulsifiers, salts for influencing osmotic pressure, coloring agents, alcohols and buffering agents.
58. (Previously presented) The composition of Claim 25 wherein the polyglycolized glyceride is pegicol 5-oleate; the non-aqueous carrier is cottonseed oil; and the anti-inflammatory agent comprises a selective COX-2 inhibitor.

Claims 59-61 (canceled)